Interim Analysis Of Neoadjuvant Chemoradiotherapy And Durvalumab For Potentially Resectable Stage Iii Non-Small Cell Lung Cancer (Nsclc)
Journal of Thoracic Oncology(2021)
摘要
Although definitive concurrent chemoradiotherapy (CRT) is considered standard of care for most stage III NSCLC patients, neoadjuvant-CRT (N-CRT) followed by surgery is an accepted practice with a potential survival benefit. Regarding synergistic effects of combining PD-1/PD-L1 blockade to CRT, we designed a two-stage phase Ib trial (ACTS-30) which assesses the safety and feasibility of the combination of N-CRT with durvalumab (PD-L1 inhibitor) in potentially resectable stage III NSCLC (ClinicalTrials.gov identifier: NCT03694236).
更多查看译文
关键词
Neoadjuvant, Immunotherapy, chemoradiotherapy
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要